Table 3.
Chi-squareddistribution of ESBL factors and antibiotic resistance in different ST-types
| No (%) of the isolates | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ST131; n(%) | Other STs; n (%) | |||||||||||||||||||||
| Resistance traits | All isolates (n = 155) | All ST131 (n = 71) | Non H30 (n = 35) | H30 (n = 36) | ST405 (n = 28) | ST168 (n = 16) | ST29 (n = 13) | ST69 (n = 5) | ST95 (n = 2) | ST31 (n = 2) | ST10 (n = 2) | ST448 (n = 2) | ST89 (n = 2) | ST703 (n = 2) | ST910 (n = 1) | ST545 (n = 1) | ST971 (n = 1) | ST153 (n = 1) | ST152 (n = 1) | ST12 (n = 1) | ST838 (n = 1) | NSC (n = 3) |
| ESBL phenotypes | 65(42) | 30(42) | 15(43) | 15(42) | 13(46) | 8(50) | 7(54) | 2(40) | 00 | 00 | 1(50) | 00 | 1(50) | 00 | 00 | 00 | 00 | 00 | 1(100) | 00 | 00 | 2(67) |
| blaCTX-M-15 | 57(39) | 27(38) | 12(34) | 15(42) | 11(39) | 8(50) | 6(46) | 2(40) | 00 | 00 | 1(50) | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 2(67) |
| blaTEM | 23(15) | 8(11) | 5(14) | 3(8) | 5(18) | 5(31) | 3(23) | 2(40) | 00 | 00 | 1(50) | 00 | 1(50) | 00 | 00 | 00 | 00 | 00 | 1(100) | 00 | 00 | 00 |
| blaSHV | 6(4) | 3(4) | 1(3) | 2(6) | 1(4) | 2(13) | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 00 |
| blaOXA | 10(6) | 6(8) | 3(9) | 3(8) | 3(11) | 1(6) | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 00 |
| blaPSE | 1(0.6) | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 1(100) | 00 | 00 | 00 | 00 | 00 | 00 | 00 |
| Piperacillin tazobactam | 7(5) | 3(4) | 2(6) | 0(0) | 3(11) | 2(13) | 00 | 00 | 1(50) | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 00 |
| Ceftazidime | 96(62) | 43(61) | 20(57)7 | 23(64) | 20(71) | 10(63) | 9(69) | 5(100) | 1(50) | 00 | 00 | 00 | 1(50) | 2(100) | 1(100) | 00 | 00 | 00 | 00 | 1(100) | 00 | 00 |
| Cefotaxime | 101(65) | 46(65) | 22(63) | 24(67) | 20(71) | 10(63) | 9(69) | 5(100) | 2(100) | 00 | 1(50) | 1(50) | 1(50) | 2(100) | 1(100) | 00 | 00 | 00 | 1(100) | 00 | 00 | 00 |
| Ceftriaxone | 99(64) | 46(65) | 25(71) | 21(58) | 21(75) | 10(63) | 9(69) | 2(40) | 1(50) | 00 | 00 | 1(50) | 1(50) | 1(50) | 1(100) | 1(100) | 00 | 00 | 1(100) | 1(100) | 1(100) | 2(67) |
| Ciprofloxacin | 95(61) | 45(63) | 23(66) | 22(61) | 18(64) | 13(81) | 6(46) | 4(80) | 2(100) | 1(50) | 1(50) | 1(50) | 00 | 2(100) | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 2(67) |
| Levofloxacin | 97(63) | 45(63) | 24(69) | 21(58) | 19(68) | 14*(88) | 6(46) | 4(80) | 2(100) | 1(50) | 2(100) | 00 | 2(100) | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 2(67) |
| Amikacin | 7(5) | 4(6) | 2(6) | 2(6) | 00 | 1(6) | 1(8) | 1(20) | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 00 |
| Gentamicin | 47(30) | 21(30) | 11(31) | 10(28) | 10(36) | 5(31) | 3(23) | 1(20) | 2(100) | 00 | 1(50) | 1(50) | 00 | 2(100) | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 1(33) |
| Amoxicillin-clavulanic acid | 111(72) | 48(68) | 25(71) | 23(64) | 22(79) | 10(63) | 9(69) | 2(40) | 00 | 00 | 00 | 1(50) | 1(50) | 1(50) | 1(100) | 1(100) | 00 | 00 | 1(100) | 1(100) | 1(100) | 2(67) |
| Trimethoprim sulfonamides | 130(84) | 61(86) | 30(86) | 31(86) | 24(86) | 13(81) | 10(77) | 4(80) | 2(100) | 1(50) | 1(50) | 1(50) | 2(100) | 2(100) | 1(100) | 1(100) | 1(100) | 1(100) | 1(100) | 1(100) | 00 | 3(100) |
| Nitrofurantoin | 9(6) | 9(13)*** | 6(17)*** | 3(8) | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 00 | 00 |
| Fosfomycin | 15(10) | 9(13) | 3(9) | 6(17) | 00 | 2(13) | 00 | 00 | 00 | 1(50) | 00 | 1(50) | 1(50) | 00 | 00 | 00 | 00 | 00 | 1(100) | 00 | 00 | 00 |
Distribution of antibiotic resistance of uropathogenic E. coli (n = 155) among different sequence types. The p values were calculated by comparing individual STswith each other. The table correlates different traits in vertical columns among different sequence types. The percentages were calculated with reference to total number of sequence types
*P < 0.05, *** P ≤ 0.001